|Bid||71.38 x 800|
|Ask||71.52 x 1300|
|Day's Range||71.01 - 73.38|
|52 Week Range||62.31 - 287.79|
|Beta (3Y Monthly)||2.14|
|PE Ratio (TTM)||34.61|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||103.50|
Inogen Inc NASDAQ/NGS:INGNView full report here! Summary * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for INGN with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on May 16. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold INGN had net inflows of $1.15 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Warning! GuruFocus has detected 3 Warning Signs with IRDM. The risk is very high with this kind of investment, but if investors look for companies that have no debt and a moderate to high current ratio, the risk can be significantly decreased. In addition, the companies have received an overweight recommendation rating from Wall Street, increasing the chances of a successful bet as these stocks are expected to outperform their industries within 12 months.
Today we'll look at Inogen, Inc. (NASDAQ:INGN) and reflect on its potential as an investment. To be precise, we'll...
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Inogen, Inc. , a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company’s management will be participating in the 39th Annual William Blair Growth Stock Conference in Chicago.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Stocks that moved substantially or traded heavily on Wednesday: Zayo Group Holdings Inc., up $2.38 to $33 The fiber optic infrastructure company said it is being bought by Digital Colony and EQT for $14.3 ...
The Goleta, California-based company said it had profit of 24 cents per share. The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...
It's been a busy Tuesday as usual and a lot of stocks such as Electronic Arts Inc. (NASDAQ:EA), Kinross Gold Corporation (NYSE:KGC), Inogen Inc (NASDAQ:INGN), Supernus Pharmaceuticals Inc (NASDAQ:SUPN), and 3D Systems Corporation (NYSE:DDD) are on the move in extended market trading after market close. Let's analyze why each stock is on the move and how the smart money, hedge funds […]
Inogen Inc. shares dropped in the extended session Tuesday after the maker of oxygen therapy systems missed Wall Street earnings targets and cut its outlook for the year. Inogen shares, which had been briefly halted, dropped 20% after hours, following a 4.2% decline to close the regular session at $91.14. The company reported first-quarter net income of $5.3 million, or 24 cents a share, compared with $10.8 million, or 48 cents a share, in the year-ago period. Revenue rose to $90.2 million from $79.1 million in the year-ago quarter. Analysts surveyed by FactSet had forecast earnings of 30 cents a share on revenue of $89.6 million. Inogen reduced its forecast revenue for the year to a range of $405 million to $415 million, down from a range of $430 million to $440 million. Analysts had forecast revenue of $433.8 million.
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq.
Law Offices of Howard G. Smith reminds investors of the upcoming May 6, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Inogen, Inc. (“Inogen” or the “Company”) (NASDAQ: INGN) securities between November 8, 2017 and February 26, 2019, inclusive (the “Class Period”). Investors suffering losses on their Inogen investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to firstname.lastname@example.org.
NEW YORK, NY / ACCESSWIRE / May 6, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested ...
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Inogen, Inc. (“Inogen” or “the Company”) (NASDAQ: INGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.